Pursuant to Regulation 30 of the Listing Obligations and Disclosure Requirements Regulations, 2015, we wish to inform you that officials of the Food and Drug Administration (FDA), Nashik, ....
ELITECON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Food and Drug Administration (FDA), Nashik conducted an inspection at Elitecon International's manufacturing facility in Talegaon, Dindori on January 8, 2026, under the Food Safety and Standards Act, 2006, related to tobacco products covered by a Maharashtra government notification dated July 20, 2025. During the inspection, certain tobacco inventories and one packing and sealing machine were seized by the authorities, and the matter is currently under review. The company states that other business operations continue normally with no material impact on overall operations or going concern status, though the financial impact cannot be quantified at this stage. Notably, the disclosure itself was delayed, and the company issued a separate letter explaining the delay was unintentional and occurred during fact verification and legal evaluation.
The seizure of inventory and machinery at the Nashik facility creates near-term uncertainty for the company's tobacco-related operations, though management claims no material impact. Investors should monitor the regulatory outcome, as potential penalties, product restrictions, or further enforcement actions could affect financials, and the delayed disclosure may also raise governance concerns.